Previous reports demonstrated that an increase in circulating A-FABP level was associated with several metabolic disorders and CVDs, such as obesity, diabetes mellitus (DM), hypertension (HTN), and cardiac dysfunction [10,11,12]. Here, FABP4 is linked to obesity disorder.